ISHARES BIOTECHNOLOGY ETF
1.93 | 1.52%
1.93 | 1.52%
30d. avg volume.
127.58 - 129.34
104.29 - 138.74
News and Commentary
FDA Approves Alzheimer's Drug Slowing Cognitive Decline The Food and Drug Administration (FDA) announced accelerated approval for lecanemab which showed evidence that it was able to slow cognitive decline in people with mild impairmen...
Here’s Why Investors Should Consider Biotech, Pharmaceutical Stocks The financial markets are not the most pleasant and calm place right now. It's facing risks in multiple areas such as geopolitics, inflation, and economic growth. There's also th...
Biotech ETFs May Need to Prepare for More Losses Ahead Biotechnology stocks faced their worst April on record, and more pain may be ahead for biotech-focused exchange traded funds (ETF).Popular biotech-focus...
Biotechs Setting up for a Strong 2021 From 2009 to the middle of 2015, biotechs were one of the strongest sectors in the market. Over this period, the iShares Nasdaq Biotechnology ETF
Biotechs Setting Up, Fundamentals Improving The biotech sector is exhibiting remarkable strength and resilience during these turbulent market conditions. Interestingly, biotechs were actually a laggard during the last leg...
Gene Editing Stocks Could Power Next Leg of Biotech Bull Market Since this current bull market began in March 2009, one of the leading sectors has been biotech stocks
ETF Weekly: Industry Leaders Discuss 2020 Trends at Inside ETFs As exchange-traded fund industry leaders are meeting for the Inside ETFs, the world's largest ETF conference, this week, let's take a look at the latest trends that will be discu...